Research advances in the role of CD8+ T cells in the tumor microenvironment of endometrial cancer

Hu Yu, Wei Hua, Zhou Zhou, Zhang Sanyuan

PDF(585 KB)
PDF(585 KB)
Journal of Chongqing Medical University ›› 2025, Vol. 50 ›› Issue (05) : 589-594. DOI: 10.13406/j.cnki.cyxb.003765
Precision Medicine in Cancer and Translational Studies

Research advances in the role of CD8+ T cells in the tumor microenvironment of endometrial cancer

Author information +
History +

Abstract

Endometrial cancer（EC） is one of the common malignant tumors of the female reproductive system，and the conventional treatment methods including surgery and radiochemotherapy have a limited therapeutic effect. CD8+ T cells are the main effector cells in tumor microenvironment（TME） and are also the main target cells for immunotherapy that have emerged in recent years. This article briefly elaborates on the cytotoxic effect of CD8+T cells in TME through the three pathways of the perforin-granzyme pathway，the FAS pathway，and the secretion of cytokines，and the changes in the peripheral environment of patients with EC may affect the functions of CD8+ T cells. This article also summarizes the application of CD8+ T cells as the targets for EC treatment，in order to provide new ideas for clinical treatment.

Key words

CD8+ T cells / endometrial cancer / tumor environment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Hu Yu , Wei Hua , Zhou Zhou , et al. Research advances in the role of CD8+ T cells in the tumor microenvironment of endometrial cancer. Journal of Chongqing Medical University. 2025, 50(05): 589-594 https://doi.org/10.13406/j.cnki.cyxb.003765

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Amant F， Moerman P， Neven P，et al. Endometrial cancer[J]. Lancet，2005，366（9484）：491-505．
本文引用 [1]
2
陈晓军，张剑峰，陆 雯，等. 子宫内膜癌手术治疗质量控制与评价标准中国专家共识（2024年版）[J]. 中国实用妇科与产科杂志，2024，40（6）：626-637．
Chen XJ， Zhang JF， Lu W，et al. Chinese expert consensus on quality control and quality indicators forsurgical treatment of endometrial carcinoma（2024 edition）[J]. Chin J Pract Gynecol Obstet，2024，40（6）：626-637．
本文引用 [1]
3
Thommen DS， Schumacher TN. T cell dysfunction in cancer[J]. Cancer Cell，2018，33（4）：547-562．
本文引用 [1]
4
纪　元，陈明洋. CD8+T细胞在肿瘤免疫中的研究进展[J]. 解剖科学进展，2024，30（4）：440-442．
Ji Y， Chen MY. Research progress of CD8+T cells in tumor immunity[J]. Prog Anat Sci，2024，30（4）：440-442．
本文引用 [1]
5
Obar JJ， Lefrançois L. Memory CD8+T cell differentiation[J]. Ann N Y Acad Sci，2010，1183：251-266．
本文引用 [1]
6
Dolina JS， Van Braeckel-Budimir N， Thomas GD，et al. CD8+T cell exhaustion in cancer[J]. Front Immunol，2021，12：715234．
本文引用 [1]
7
Golstein P， Griffiths GM. An early history of T cell-mediated cytotoxicity[J]. Nat Rev Immunol，2018，18（8）：527-535．
本文引用 [1]
8
Patel MV， Shen Z， Rodriguez-Garcia M，et al. Endometrial cancer suppresses CD8+T cell-mediated cytotoxicity in postmenopausal women[J]. Front Immunol，2021，12：657326．
本文引用 [4]
9
Workel HH， Komdeur FL， Wouters MCA，et al. CD103 defines intraepithelial CD8+ PD1+tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma[J]. Eur J Cancer，2016，60：1-11．
本文引用 [2]
10
Jung IK， Kim SS， Suh DS，et al. Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma[J]. Obstet Gynecol Sci，2014，57（4）：266-273.
本文引用 [2]
11
Montfort A， Colacios C， Levade T，et al. The TNF paradox in cancer progression and immunotherapy[J]. Front Immunol，2019，10：1818．
本文引用 [1]
12
Aqbi HF， Wallace M， Sappal S，et al. IFN-γ orchestrates tumor elimination，tumor dormancy，tumor escape，and progression[J]. J Leukoc Biol，2018，103（6）：1219.
本文引用 [1]
13
Rodriguez-Garcia M， Shen Z， Fortier JM，et al. Differential cytotoxic function of resident and non-resident CD8+T cells in the human female reproductive tract before and after menopause[J]. Front Immunol，2020，11：1096．
本文引用 [2]
14
Yang J， Yan J， Liu BR. Targeting VEGF/VEGFR to modulate antitumor immunity[J]. Front Immunol，2018，9：978．
本文引用 [1]
15
Asaka S， Yen TT， Wang TL，et al. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers[J]. Mod Pathol，2019，32（4）：576-584．
本文引用 [1]
16
Musacchio L， Boccia SM， Caruso G，et al. Immune checkpoint inhibitors：a promising choice for endometrial cancer patients?[J]. J Clin Med，2020，9（6）：1721．
本文引用 [2]
17
Bruno V， Corrado G， Baci D，et al. Endometrial cancer immune escape mechanisms：let us learn from the fetal-maternal interface[J]. Front Oncol，2020，10：156．
本文引用 [1]
18
Mulati K， Hamanishi J， Matsumura N，et al. VISTA expressed in tumour cells regulates T cell function[J]. Br J Cancer，2019，120（1）：115-127．
本文引用 [1]
19
Karpathiou G， Chauleur C， Mobarki M，et al. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix[J]. Pathol Res Pract，2020，216（1）：152782．
本文引用 [1]
20
Ramos A， Fortin SAM， Melchert V，et al. Checkpoint inhibitor signatures across endometrial carcinoma histologic subtypes[J]. Gynecol Oncol，2018，149（3）：621．
本文引用 [1]
21
Oh MS， Chae YK. Deep and durable response with combination CTLA-4 and PD-1 blockade in mismatch repair（MMR）-proficient endometrial cancer[J]. J Immunother，2019，42（2）：51-54．
本文引用 [1]
22
Anderson AC， Joller N， Kuchroo VK. Lag-3，tim-3，and TIGIT：co-inhibitory receptors with specialized functions in immune regulation[J]. Immunity，2016，44（5）：989-1004．
本文引用 [1]
23
Rodriguez AC， Blanchard Z， Maurer KA，et al. Estrogen signaling in endometrial cancer：a key oncogenic pathway with several open questions[J]. Horm Cancer，2019，10（2/3）：51-63．
本文引用 [1]
24
Kyrgiou M， Kalliala I， Markozannes G，et al. Adiposity and cancer at major anatomical sites：umbrella review of the literature[J]. BMJ，2017，356：j477．
本文引用 [1]
25
Shen Z， Rodriguez-Garcia M， Patel MV，et al. Direct and Indirect endocrine-mediated suppression of human endometrial CD8+T cell cytotoxicity[J]. Sci Rep，2021，11（1）：1773．
本文引用 [2]
26
Zhou WJ， Zhang J， Xie F，et al. CD45RO-CD8+ T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ERβ/miR-765/PLP2/Notch axis[J]. Theranostics，2021，11（11）：5330-5345．
本文引用 [1]
27
Tumeh PC， Harview CL， Yearley JH，et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature，2014，515（7528）：568-571．
本文引用 [1]
28
Robert C， Schachter J， Long GV，et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. 2015，372（26）：2521-2532．
本文引用 [1]
29
Barber DL， John Wherry E， Masopust D，et al. Restoring function in exhausted CD8 T cells during chronic viral infection[J]. Nature，2006，439（7077）：682-687．
本文引用 [1]
30
Knisely A， Hinchcliff E， Fellman B，et al. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis[J]. Med，2024，5（4）：311-320．
本文引用 [1]
31
Sadelain M. CD19 CAR T Cells [J]. Cell，2017，171（7）：1471.
本文引用 [2]
32
Maus MV， Plotkin J， Jakka G，et al. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity[J]. Mol Ther Oncolytics，2017，3：1-9．
本文引用 [2]
33
Shank BR， Do B， Sevin A，et al. Chimeric antigen receptor T cells in hematologic malignancies[J]. Pharmacotherapy，2017，37（3）：334-345.
本文引用 [1]
34
Petersen CT， Krenciute G. Next generation CAR T cells for the immunotherapy of high-grade glioma[J]. Front Oncol，2019，9：69．
本文引用 [1]
35
Barrett DM， Grupp SA， June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street[J]. J Immunol，2015，195（3）：755-761．
本文引用 [1]
36
Landoni E， Savoldo B. Treating hematological malignancies with cell therapy：where are we now?[J]. Expert Opin Biol Ther，2018，18（1）：65-75．
37
Gargett T， Yu WB， Dotti G，et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade[J]. Mol Ther，2016，24（6）：1135-1149．
38
Tchou J， Zhao YB， Levine BL，et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor（CAR） T cells in metastatic breast cancer[J]. Cancer Immunol Res，2017，5（12）：1152-1161．
本文引用 [1]
39
Choi JY， Kim TJ. The current status and future perspectives of chimeric antigen receptor-engineered T cell therapy for the management of patients with endometrial cancer[J]. Curr Issues Mol Biol，2023，45（4）：3359-3374．
本文引用 [1]
40
Ma XY， Wang QM， Sun CG，et al. Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis[J]. Cell Rep，2023，42（8）：112944．
本文引用 [1]
41
Salas-Benito D， Pérez-Gracia JL， Ponz-Sarvisé M，et al. Paradigms on immunotherapy combinations with chemotherapy[J]. Cancer Discov，2021，11（6）：1353-1367．
本文引用 [1]
42
Sakaguchi S， Mikami N， Wing JB，et al. Regulatory T cells and human disease[J]. Annu Rev Immunol，2020，38：541-566．
本文引用 [1]
43
Gabrilovich DI. Myeloid-derived suppressor cells[J]. Cancer Immunol Res，2017，5（1）：3-8．
本文引用 [1]
44
Barber EL， Chen SQ， Pineda MJ，et al. Clinical and biological activity of chemoimmunotherapy in advanced endometrial adenocarcinoma：a phaseⅡ trial of the big ten cancer research consortium[J]. Cancer Res Commun，2022，2（10）：1293-1303．
本文引用 [1]
45
Patel SP， Alonso-Gordoa T， Banerjee S，et al. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors[J]. J Immunother Cancer，2024，12（2）：e007340．
本文引用 [1]
46
Lee L， Matulonis U. Immunotherapy and radiation combinatorial trials in gynecologic cancer：a potential synergy?[J]. Gynecol Oncol，2019，154（1）：236-245．
本文引用 [1]
47
Walle T， Monge RM， Cerwenka A，et al. Radiation effects on antitumor immune responses：current perspectives and challenges[J]. Ther Adv Med Oncol，2018，10：1758834017742575．
本文引用 [1]
48
Tuyaerts S， Van Nuffel AMT， Naert E，et al. PRIMMO study protocol：a phase Ⅱ study combining PD-1 blockade，radiation and immunomodulation to tackle cervical and uterine cancer[J]. BMC Cancer，2019，19（1）：506．
本文引用 [1]

Comments

PDF(585 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉